Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study - Single-dose Reductions in ...

--(BUSINESS WIRE)--Arrowhead Pharmaceuticals ... Our preclinical data presented at ADA suggest that INHBE reduction with siRNA is a promising new approach to address obesity and metabolic diseases ...

ARO-C3—designed to reduce liver production of complement component 3 (C3)—was tied to a greater-than-87% mean sustained reduction in C3 through week 24, according to Arrowhead. The RNAi asset ...

Arrowhead Pharmaceuticals Inc ARWR shares ... or 200 mg of fazirsiran demonstrated a dose dependent mean reduction in serum mutant alpha-1 antitrypsin protein concentration at week 48 of ...

Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA Through 29 days after initial treatment ...

Arrowhead released interim results from its ARO-RAGE phase 1/2 trial that showed 90% serum receptor for advanced glycation end products (RAGE) reduction and 80% RAGE reduction with mean maximum ...

and the maximum individual reduction was 89%. In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug Application for investigational plozasiran for ...

Additional data to be discussed at analyst event on March 25 "It's encouraging to see data from our preclinical rodent models confirmed in a true primate disease setting," said Bruce Given, MD, ...

Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA Through 29 days after initial treatment, maximal ...